{"title": "Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male", "author": "Richard A Maiella; Kelly M Staples; Ashokvardhan Veldanda", "url": "http://www.aimspress.com/rticle/doi/10.3934/Allergy.2022003", "hostname": "aimspress.com", "description": "With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster.", "sitename": "AIMS Allergy and Immunology", "date": "2022-01-10", "cleaned_text": "Case report Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male - 1. Rowan University School of Osteopathic Medicine, 42 E Laurel Rd, Stratford, NJ 08084, USA - 2. Stafford Medical, P.A., 1364 Route 72 West, Manahawkin 2022 Published: 17 February 2022 - - - - With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster. Citation: Richard A. Maiella, Kelly M. Staples, Ashokvardhan Veldanda. Migratory dermatographic urticaria following COVID-19 vaccine booster in Allergy and Immunology, 2022, 6(1): 14-18. doi: 10.3934/Allergy.2022003 - Abstract With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster. Conflict of interest The authors declare no conflict of interest. Author contributions RM: conception, design, interpretation of case presentations, writing of manuscript, revision of study material, final approval of manuscript; KS: writing of manuscript, revision of study material, final approval of manuscript; AV: served as scientific advisor and provided care for study patient, attending physician. References | [1] || (2021) U.S. Food and Drug Administration, Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters.FDA. Available from: |[https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters) | [2] || Mathieu E, Ritchie H, Ortiz-Ospina E, et al. (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 947-953. HM, Essink B, et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. J et al. (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to Dermatol 39: Chatim A, et al. (2021) Chronic spontaneous urticaria al. Delayed localized hypersensitivity reactions to case series. JAMA Dermatol 157: 716-720. |[https://doi.org/10.1001/jamadermatol.2021.1214](https://doi.org/10.1001/jamadermatol.2021.1214) - - - - "}